Reliable Data You Can Trust
Reliable Data You Can Trust
A recent report published by Infinium Global Research on
anti-obesity prescription drugs market provides in-depth analysis of segments
and sub-segments in global as well as regional anti-obesity prescription drugs
market. The study also highlights the impact of drivers, restraints, and macro
indicators on the global and regional anti-obesity prescription drugs market
over the short term as well as long term. The report is a comprehensive
presentation of trends, forecast and dollar values of global anti-obesity
prescription drugs market. According to the report the global anti-obesity
prescription drugs market was worth USD 348 million in 2016 and it is projected
to reach USD 1095 million by 2024, growing at a CAGR of 4.97% over the forecast
period of 2018-2024.
The pharmacological agents that help to reduce
or control weight. Anti-obesity drugs help in reducing body mass either by
reducing the hunger or increasing the consumption of calories. The ingesting of
unhealthy food which is rich in cholesterol has increased which leads to a rise
in demand for anti-obesity prescription drugs. The rising level of chronic stress
also contributes to obesity. Rising consumption of alcoholic beverages and
unhealthy food which is rich in cholesterol that leads to obesity is driving
the growth of the market. Growing occurrence of depression has led to growing
consumption of the psychotropic drugs; the side effect of this drug is increasing
which result in obesity. Moreover, increasing incidences of diabetes have surged
up the consumption of medications. These medications have appetite stimulating
features, due to which the patients incline to eat more. Eating disorders due
to antidepressants and diabetic drugs increase the diet which has sustained to
contribute towards obesity. Growing demand for obesity management is expected
to impact the growth of the global anti-obesity prescription drugs market
positively.
The report on global anti-obesity prescription drugs market covers
segments such as drug class, distribution channel and age group. On the basis
of drug class, the global anti-obesity prescription drugs market is categorized
into orlistat, phentermine, and topiramate, bupropion, and naltrexone, lorcaserin
and liraglutide. On the basis of distribution channel the global anti-obesity
prescription drugs market is categorized into retail pharmacy, hospital
pharmacy, and online pharmacy. On the basis of age group the global anti-obesity
prescription drugs market is categorized into pediatric and adult.
The report provides regional analysis covering geographies such as
North America, Europe, Asia-Pacific, and Rest of the World. In this section, the
key trends and market size for each geography is provided over the period of
2016-2024. The countries covered in the North America region include the U.S.,
Canada, and Mexico; while Asia-Pacific includes China, Japan, India, South
Korea, Malaysia, and among others. Moreover, Germany, U.K., France, Spain, and
Rest of Europe are included in the European region. The U.S. drives the growth
in the North America region as it is the largest market in the region. The
Asia-pacific region offers a substantial potential for the market growth owing
to rapid growth in markets such as India and China. Countries such as the U.S., the U.K., and
France among others has reported a substantial rise in the obesity population.
Moreover, growing work stress in emerging markets of Asia-pacific is likely to
cause rise in obesity cases in the years to come over the next six years.
According to the study, North America followed by Europe accounted for the
largest market share in the word anti-obesity prescription drugs market in 2016
and this trend is projected to continue over the forecast period, with
increasing awareness among the people in the U.S. and Canada.
The report provides profiles of the companies in the global
anti-obesity prescription drugs market such as F Hoffmann La Roche Ltd,
Orexigen Therapeutics, Inc, Novo Nordisk A/S, Arena Pharmaceuticals, Inc,
GlaxoSmithKline, VIVUS, Inc, Boehringer Ingelheim, Alizyme and Others. Recently
approved Saxenda by Novo Nordisk is growing at a fast growth rate due to rising
interest among obese people.Novo Nordisk, an innovator of drugs in the obesity
market introduces Saxenda in all the major markets with a higher dose of
glucagon-like peptide-1 (GLP-1) receptor agonist, liraglutide, This Dual
therapy can be used for both obesity and type 2 diabetes is the latest trend in
the market.
The report provides deep insights on demand forecasts, market trends, and micro and macro indicators. In addition, this report provides insights into the factors that are driving and restraining the global anti-obesity prescription drugs market. Moreover, IGR-Growth Matrix analysis given in the report brings an insight into the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter's five forces analysis and DRO analysis of anti-obesity prescription drugs market. Moreover, the study highlights current market trends and provides forecast from 2018-2024. We also have highlighted future trends in the anti-obesity prescription drugs market that will impact the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight into the market share of the leading players. This report will help manufacturers, suppliers, and distributors of the anti-obesity prescription drugs market to understand the present and future trends in this market and formulate their strategies accordingly.
Please Choose One of them.